Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Cash cushion • No revenue • Ongoing losses ELVN has a very strong balance sheet with ample cash and investments and minimal leverage, but its lack of revenue and persistent losses make future execution the key driver of value.
Price Behavior
Key Price Behavior Insights: • Higher highs • Breakout support • Stretched rally Support Level: $58.04 Resistance Level: $61.11 ELVN has been in a strong uptrend over the last month, holding above the $53–$54 breakout zone and $58.04 support, but the rapid move to $61.11 leaves it near resistance and vulnerable to a short-term pullback.
Sentiment & News
Key News Insights: • Phase 1 efficacy • FDA trial alignment • Strong cash runway Enliven Therapeutics posted encouraging ELVN-001 Phase 1 data, aligned with the FDA on Phase 3 design, and backed it with a strong cash runway as institutional ownership rose.
AI Summary
ELVN has shifted from a cash-burning biotech to a well-funded, clinically validated story with a clearer Phase 3 path, but after the rerating the investment now hinges on ELVN-001 continuing to deliver strong data—if upcoming results disappoint, the stock could quickly give back gains despite low financing risk.
Description
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors for cancer treatment. Its lead programs include ELVN-001, in a Phase 1 study for chronic myeloid leukemia, and ELVN-002, recently activated in a Phase 1 trial for tumors with HER2 alterations; the company is headquartered in Boulder, Colorado.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 26 | Apr 2 | ELVN | Enliven Therapeutics, Inc. | ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade. | Closed | -1.2% |